Kazia Therapeutics Ltd Stock Alpha and Beta Analysis
| KZIA Stock | USD 7.57 0.43 5.37% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kazia Therapeutics Ltd. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kazia Therapeutics over a specified time horizon. Remember, high Kazia Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kazia Therapeutics' market risk premium analysis include:
Beta 5.18 | Alpha 0.0879 | Risk 11.25 | Sharpe Ratio 0.0518 | Expected Return 0.58 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Kazia Therapeutics Backtesting, Kazia Therapeutics Valuation, Kazia Therapeutics Correlation, Kazia Therapeutics Hype Analysis, Kazia Therapeutics Volatility, Kazia Therapeutics History and analyze Kazia Therapeutics Performance. Kazia Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kazia Therapeutics market risk premium is the additional return an investor will receive from holding Kazia Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kazia Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kazia Therapeutics' performance over market.| α | 0.09 | β | 5.18 |
Kazia Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Kazia Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Kazia Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Kazia Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Kazia Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kazia Therapeutics shares will generate the highest return on investment. By understating and applying Kazia Therapeutics stock market price indicators, traders can identify Kazia Therapeutics position entry and exit signals to maximize returns.
Kazia Therapeutics Return and Market Media
The median price of Kazia Therapeutics for the period between Mon, Sep 29, 2025 and Sun, Dec 28, 2025 is 7.6 with a coefficient of variation of 27.63. The daily time series for the period is distributed with a sample standard deviation of 2.36, arithmetic mean of 8.53, and mean deviation of 1.79. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Kazia Therapeutics Announces 86 percent Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regime... | 10/02/2025 |
2 | Novogen Limited Sees Large Decline in Short Interest | 10/20/2025 |
3 | Acquisition by Austin Josiah T of 6100 shares of Kazia Therapeutics at 10.4198 subject to Rule 16b-3 | 10/28/2025 |
4 | Kazia Therapeutics Achieves Initial iCR in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, I | 11/18/2025 |
5 | Kazia Therapeutics Announces Pricing of 50.0 Million Private Placement of Equity Securities | 12/02/2025 |
6 | Kazia Therapeutics closes 46.5M private placement amid Nasdaq review - Stock Titan | 12/05/2025 |
7 | Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisibs Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Adva | 12/10/2025 |
8 | 12 Health Care Stocks Moving In Tuesdays Intraday Session - Benzinga | 12/16/2025 |
9 | Is the Market Bullish or Bearish on Kazia Therapeutics Ltd | 12/26/2025 |
About Kazia Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kazia or other stocks. Alpha measures the amount that position in Kazia Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 4.87 | 1.32 | 1.52 | 1.44 | Revenue Per Share | 0.001506 | 4.81 | 5.53 | 5.26 |
Kazia Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Kazia Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kazia Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kazia Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kazia Therapeutics. Please utilize our Beneish M Score to check the likelihood of Kazia Therapeutics' management manipulating its earnings.
| 4th of January 2024 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 29th of August 2024 Next Fiscal Year End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Build Portfolio with Kazia Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Kazia Therapeutics Backtesting, Kazia Therapeutics Valuation, Kazia Therapeutics Correlation, Kazia Therapeutics Hype Analysis, Kazia Therapeutics Volatility, Kazia Therapeutics History and analyze Kazia Therapeutics Performance. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Kazia Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.